Sonova Holding AG (Sonova) is a provider of hearing systems and wireless communication systems for all groups of people with hearing impairment. It offers a comprehensive range of hearing instruments and cochlear implant solutions under brands such as Phonak, Unitron, Advanced Bionics, AudioNova and Sennheiser.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sonova operates multiple research and development hubs worldwide to support continuous innovation. These hubs collaborate closely with internal development and commercial teams, as well as with external research institutions. The company has developed a holistic hearing care framework that focuses on understanding the benefits of hearing care across multiple dimensions, including cognitive, physical, and socio-emotional well-being, as well as quality of life. This framework is applied across Sonova's businesses, particularly in research activities, awareness initiatives, and training for hearing care professionals. During the 2025/26 financial year, multiple research studies were initiated based on this framework, with an increased focus on translating new insights into clinical practice. Sonova’s research and development activities are centralized in Switzerland, with supporting activities in Canada and Germany. The company also has R&D initiatives for Advanced Bionics, which are centralized predominantly in the United States and Switzerland. These units are responsible for the design, development, and innovation of hearing instruments and cochlear implants, ensuring compliance with regulatory and scientific standards. As of March 2026, the company filed 44 new patent applications and owned 2000 active granted patents and design rights. In FY2026, the company spent CHF217.7 million on its R&D activities, which grew 1.5% YoY..As of March 31, 2026, the company had 1,269 employees serving in the R&D division.